



**PREMIER
MINISTRE**

*Liberté
Égalité
Fraternité*

Secrétariat général pour l'investissement



PROGRAMME
DE RECHERCHE
BIOTHÉRAPIES

Webinaire – Soutien au dépôt de projets européens

11/06/2026

Agenda

- **Presentation of the support offered by the PEPR and the selection criteria for supported projects**
- **Presentation of upcoming European calls for proposals**
- **Presentation of the support offered by ABGI**
- **Q&A session**

Support initiatives

Education & Training

- Master's degree scholarships
- Access to e-learning courses
- Participation to training programs and summer schools
- International mobility grants for young scientists
- Welcoming international senior researchers

Communication & Dissemination

- Sponsoring the organization of events/seminars/conference
- Travel grants to participate to conferences

European Visibility

- Support for submitting applications to European calls

Support for submitting applications to European calls

Context: Supporting the visibility of French public institutes funded by the PEPR-BBTI program in Europe within the field of biotherapy and bioproduction and promote the follow-up of projects funded by the PEPR.

Action: Providing assistance to submit European projects coordinated by French public institutions supported (=financed) by the PEPR-BBTI program, by responding to calls for proposals such as:

Horizon Europe RIA (Research and Innovation Actions), IA (Innovation Actions), and CSA (Coordination and Support Actions)—for instance, in Cluster 1 – Health, MSCA (Marie Skłodowska-Curie Actions) Doctoral Networks, ERC Synergy Grants, EIC Pathfinder Open and/or Challenges, the Innovative Health Initiative, and calls from the new European program that will replace Horizon Europe starting in 2028 (2028–2034, currently being defined).

What is the support for?

1. Designing the work plan for the proposal building and the project implementation
2. Writing the proposal (technical part)
3. Completing the administrative forms

Eligibility criteria

1. A French public institution supported by the PEPR-BBTI (participating in at least one project already funded by the program), is coordinating the European project proposal receiving setup assistance;
2. Project topic aligned with the research pillars of the PEPR-BBTI;

Application form - Processus de candidature

1. Submit to <https://www.eva3.inserm.fr/>
2. **Deadline: at least 4 months before the proposal deadline**

Informations to be provided in the application form:

- 1) Identity – Applicant
- 2) Project details (title, keywords, target call, abstract)
- 3) Consortium: Coordinator & partners
- 4) Cover letter explaining the scientific excellence and impact of the project
- 5) CV of the coordinator

Evaluation procedure

Each application will be evaluated by the governance team and international experts (SAB). Evaluation will start once the application process is closed on Eva3.

Evaluation criteria:

1. Eligibility
2. Scientific excellence & Impact
3. Pertinence with the PEPR-BBTI pillars (axes of research)
4. Pertinence and consistency of the proposed consortium with the intended call


The applications that will be positively evaluated will be put in contact with ABGI to start the proposal building according to their proposed methodology, at least 3 months before the submission deadline

Budget and other considerations

Total budget: 400,000 € (until 2030)

Number of proposals that we can support in total: 10-15 (3-4 year)

Only one proposal per call will be supported (to avoid internal competitions)





**PREMIER
MINISTRE**

*Liberté
Égalité
Fraternité*

Secrétariat général pour l'investissement



PROGRAMME
DE RECHERCHE

BIOTHÉRAPIES

Retrouvez toutes nos actualités



[pepr-biotherapies.fr](https://www.linkedin.com/company/pepr-biotherapies)

OPPORTUNITES DE FINANCEMENTS EUROPEENS | HORIZON EUROPE – PEPR BIOTHERAPIES– 11/06/2026

Aude RAIMBAULT
Chargée de mission Cluster
Santé, Mission Cancer
Cellule Europe Inserm
aude.raimbault@inserm.fr



LA CELLULE EUROPE DE L'INSERM

Pôle Relations Européennes (PRE)




Guillaume Fusai

Responsable du Pôle Europe



Laurence Garric

ERC



Aude Raimbault

Cluster Santé (IHI -
EDCTP3), mission cancer



Marie Anson

EIC Pathfinder



Ivone Alves

Communication

Département des Ressources Humaines (DRH)



Morgane Bureau

Actions Marie S. Curie



Département des Affaires Financières (DAF)



Marion Di Maria

Aspects Juridiques et Financiers



cellule.europe@inserm.fr



[Plan d'action pour la mise en œuvre de la stratégie européenne de l'Inserm](#)

POUR VOUS, UN ENSEMBLE D'ACTEURS POUR RÉALISER VOTRE OBJECTIF HORIZON EUROPE

CELLULE EUROPE / SIÈGE



- **Identification** de l'instrument pertinent en fonction de votre projet
- Vérification de l'adéquation du projet avec l'appel que vous avez ciblé
- **Analyse** des facteurs de succès dans les projets gagnants, conseils d'écriture
- Règles de participations, aide à la recherche de partenaires (PME, SHS notamment)
- Mise en relation avec lauréats
- Statistiques
- Relecture (ERC et MSCA)
- **Accompagnement** pour l'oral ERC (oraux blancs avec panélistes et lauréats)

Si mandat de gestion
Inserm

VOTRE DÉLÉGATION RÉGIONALE

- Accompagnement au montage budgétaire et juridique
- Gestion financière du projet s'il est sélectionné

INSERM TRANSFERT



- Pour **la coordination de projets avec plusieurs partenaires** (*Cluster Santé, IHI, EDCTP3, ERC PoC, ERC SyG, MSCADoctoral Networks & Staff Exchanges*)
- Chef de projet dédié
- Planification, structuration, contribution à la rédaction
- Organisation administrative
(collecte des données des partenaires, réunions, soumission)
- **Frais de montage pris en charge par le siège**

PROJETS INDIVIDUELS

PROJETS COLLABORATIFS

Développer **ma propre équipe** autour d'un projet d'excellence scientifique de mon choix

European
Research
Council

MSCA
Doctoral
Networks

Recruter un ou des **doctorant(s)** dans le cadre d'un projet de recherche collaboratif

Recruter un **post-doctorant** pour développer un projet de recherche

MSCA
Postdoctoral
fellowships

**PI/Equipe/
Unité**

MSCA
Staff
Exchanges

Echanger des bonnes pratiques, des compétences et des savoirs *via* des **mobilités de tout type de personnel** impliqué dans un projet de recherche

Développer un projet de recherche et **acquérir de nouvelles compétences** *via* une mobilité

MSCA
Postdoctoral
fellowships

Cluster Santé
Mission Cancer

Développer un **projet** en réponse aux défis majeurs de l'Europe en matière de santé avec un **impact sociétal et économique**

EIC Pathfinder


Développer une **technologie de rupture, risquée**, mais qui mène à un changement de paradigme, avec une vision marché à 10/15 ans



ERC : LES FINANCEMENTS WP2027

[WP 2026 ERC](#)

Tous les domaines de la science
Appel blanc



Indépendance : Publication comme auteur principal avec ou sans la participation du chef de thèse


Preuve d'indépendance (scientifique, financière..)

Track-record sur 10 ans

Tous stade de carrière
Tous domaines


Ouverture AAP 2026	9/07/2025	25/09/2025	28/05/2026	10/07/2025
Deadline AAP 2026	14/10/2025	13/01/2026	27/08/2026	05/11/2025
Budget (EUR, m)	705	673	747	500
Estimated Number of Grants	450	328	294	49

AMSC | DOCTORAL NETWORKS (1/2)




Pourquoi viser les Doctoral Networks ?

- Développer un projet de recherche commun avec un réseau d'organismes européens/internationaux
- Former une nouvelle génération de chercheurs aux enjeux d'aujourd'hui et de demain




Mécanismes : 3 modèles possibles

- DN « Regular » : doctorants inscrits dans un programme doctoral
- DN - Industrial Doctorates : doctorants inscrits dans un programme doctoral + **min. 50% de leur temps de travail dans le secteur non académique**
- DN - Joint Doctorates : programme doctoral menant à l'obtention par chaque doctorant **d'un diplôme double, multiple ou conjoint**



Durée de vie du projet / du recrutement & taille du réseau

	DN « Regular »	DN-ID	DN-JD
Projet	max. 48 mois		max. 60 mois
Recrutement	de 3 à 36 mois		de 3 à 48 mois
Taille du réseau	540 personne-mois (max. 15 doctorants pour 36 mois)		540 personne-mois (max. 11 doctorants pour 48 mois)



Calendrier

- Fréquence : un appel par an | **Appel DN 2026** : 28 mai 2026 - 24 novembre 2026

AMSC | DOCTORAL NETWORKS (2/2)



Financement

- Rémunération du doctorant et indemnités spécifiques
- Coûts de fonctionnement
- Coûts de management et coûts indirects



Cible

- Les doctorants : non titulaire d'un doctorat à la date de recrutement + inscription en école doctorale
- Règle de mobilité : **pas plus de 12 mois** au cours des trois dernières années dans le pays du bénéficiaire **à la date du premier jour de recrutement**



Consortium

- Bénéficiaires : au minimum 3 organismes localisés dans 3 Etats membres ou pays associés différents (obligatoirement 1 basé dans un Etat membre). Ils ont l'obligation de recruter **au moins 1 doctorant** et **signent** le Grant Agreement
- Partenaires associés : ils **complètent** le consortium en accueillant un ou plusieurs doctorant(s) en secondment et/ou en participant au programme de formation. Ils **ne signent pas** le Grant Agreement.



Restriction

- Moins de 80 % : **impossible** de déposer une nouvelle candidature l'année suivante avec une **proposition similaire**, c'est-à-dire une proposition qui présente des changements mineurs et dans laquelle certains membres du consortium actuel sont présents.



Taux de succès DN 2024

- Global : 10,60 %

—

AAP 2027

Cluster Santé— Horizon Europe



Cluster 1 Health



CLUSTER SANTÉ

PRIORITES POLITIQUES DE LA COMMISSION EUROPEENNE

*A European Green Deal
An economy that works for people
A Europe fit for the digital age*



+

POLITIQUES EUROPEENNES STRATEGIQUES EN MATIERE DE SANTE

*Synergies avec le programme de la DG Santé "EU4Health"
Plan Cancer: Europe's beating cancer Action plan
European Health Data Space*

PLAN STRATEGIQUE HORIZON EUROPE 2025-2027
Grandes orientations stratégiques clés + Impacts attendus

Fondements des activités et des résultats de recherche et d'innovation, qui seront définis dans les programmes de travail du pilier II d'Horizon Europe



AAP « top-down » publié dans programme de travail

Programme de travail 2026-2027 - Cluster Santé

Projet collaboratif et interdisciplinaire en réponse à un AAP de la CE

AAP 2026-2027

RÔLES POSSIBLES ET CRITÈRES D'ELIGIBILITE



PROJET COLLABORATIF

Consortium de partenaires réunis pour mener à bien un projet collaboratif et **multidisciplinaire** de recherche et développement, avec un **impact à la fois sociétal** au bénéfice du citoyen (et des patients) et **économique sur les systèmes de santé**.

2 ROLES POSSIBLES DANS LE CONSORTIUM

COORDINATEUR :

Seul interlocuteur de la CE, assure le bon déroulé du projet et de ses livrables et l'interaction avec tous les partenaires.

PARTENAIRE (Bénéficiaire) :

Responsable d'un work-package ou d'une activité

→ *Pas de nombre idéal: autant de partenaires que d'expertises nécessaires à la réalisation du projet.*

→ **En moyenne : 7 à 13 partenaires**

REGLES DE PARTICIPATION

Minimum 3 entités légales issus de 3 Etats-membres ou Etats associés différents, dont **au moins l'une d'entre elle établie dans un Etat-Membre**.

Toute entité légale peut participer (organisme, université, association de patients, entreprise privée, agences de santé publiques, agences réglementaires, PME, etc...)

[List of Participating Countries in Horizon Europe](#)

Destination 3

Lutter contre les maladies et réduire leur fardeau

<p><u>HORIZON-HLTH-2027-02-DISEASE-01- two-stage:</u> Innovative healthcare interventions for non-communicable diseases</p>	<p>2027 – 2 étapes RIA</p> <p>Deadline: 17 février 2027 (1^{ère} étape) + 16 septembre 2027 (2^{ème} étape)</p>	<p>8 projets 7-8M€/projet</p>	<p>Early-stage clinical trial(s) (for pharmacological interventions: phase 1 and phase 2 clinical trials) to validate novel or refined healthcare interventions</p> <p>Proof-of-concept of clinical safety and efficacy</p> <p>→ Preclinical research and the draft clinical trial protocol should be completed at the time of submission of the proposal</p>	<p>Cardiovascular diseases, diabetes, chronic respiratory diseases or chronic kidney diseases</p>
--	---	-----------------------------------	---	---

<p><u>HORIZON-HLTH-2027-01-DISEASE-06:</u> Development of monoclonal antibodies to prevent and treat infections from Flaviviruses</p>	<p>2027 – 1 étape RIA</p> <p>Deadline : 17 février 2027</p>	<p>4 projets 9-10 M€/projet</p>	<p>Development of existing prophylactic and therapeutic monoclonal antibody candidates</p> <p>Finalisation of the in vitro characterisation of existing monoclonal antibody candidates</p> <p>In vivo tests in at least one animal model (or, if available in humanised immune system animal models)</p> <p>If requested by regulators as pre-requisite for clinical studies, in vivo tests in a non-human primate model.</p> <p>Evaluation of antibody-dependent enhancement (ADE) risk</p> <p>Production of batches of the most promising antibody candidates (GMP standard)</p> <p>First in human clinical safety studies</p>	<ul style="list-style-type: none"> • Dengue Virus, • Tick-borne Encephalitis Virus, • Japanese Encephalitis Virus, • West Nile Fever Virus, • Yellow Fever Virus <ul style="list-style-type: none"> • Zika Virus
--	---	-------------------------------------	--	---

<p><u>HORIZON-HLTH-2027-01-DISEASE-07:</u> Development of monoclonal antibodies to prevent and treat infections from Filo- Phenui-, Picorna- and Toga Viridae</p>	<p>2027 – 1 étape RIA</p> <p>Deadline : 17 février 2027</p>	<p>4 projets 9-10 M€/projet</p>	<p>Development of existing prophylactic and therapeutic monoclonal antibody candidates</p> <p>Finalisation of the in vitro characterisation of existing monoclonal antibody candidates</p> <p>In vivo tests in at least one animal model or, if available in humanised immune system animal models</p> <p>If requested by regulators as pre-requisite for clinical studies, in vivo tests in a non-human primate model.</p> <p>Evaluation of antibody-dependent enhancement (ADE) risk</p> <p>Production of batches of the most promising antibody candidates under GMP</p> <p>First in human clinical safety studies</p>	<ul style="list-style-type: none"> • Ebola Virus • Marburg Virus • Crimean-Congo Hemorrhagic Fever Virus • Rift Valley Fever Virus • Enterovirus D68 • Chikungunya Virus
--	---	-------------------------------------	---	--

<p><u>HORIZON-HLTH-2027-01-DISEASE-08:</u> Development of innovative antimicrobials against critical pathogens resistant to antimicrobials (AMR)</p>	<p>2027 – 1 étape RIA</p> <p>Deadline : 17 février 2027</p>	<p>5 projets 8-10 M€/projet</p>	<p>Development of innovative and effective antibacterial and antifungal agents, including antibody-based therapies</p> <p>Accelerate testing of novel candidates in human trials</p> <p>Finalisation of in vivo tests in at least one animal model (or, if available in humanised immune system animal models) to demonstrate the protective function of the therapeutics deemed sufficient for moving to first clinical trials.</p> <p>If requested by regulators as enablers for clinical studies, in vivo tests in a non-human primate model.</p> <p>Production of batches of the most promising antimicrobials candidates (GMP)</p> <p>In human clinical safety and efficacy studies</p>	<p><u>At least 1 on the following critical pathogens:</u></p> <p>Carbapenem resistant Acinetobacter Baumannii (CRAB).</p> <p>Carbapenem-resistant Enterobacterales (CRE) and third-generation cephalosporin-resistant Enterobacterales (C3GRE)</p> <p>Carbapenem resistant Pseudomonas Aeruginosa.</p> <p>Methicillin-Resistant Staphylococcus aureus (MRSA)</p> <p>(Drug)-resistant Aspergillus fumigatus</p> <p>(Drug)-resistant <i>Candida spp.</i></p> <p>Not pursue the development of phage-therapies</p>
---	---	-------------------------------------	--	---

<p><u>HORIZON-HLTH-2027-02-DISEASE-14- two-stage:</u> Clinical trials for advancing innovative interventions for neurodegenerative diseases</p>	<p>2027 – 2 étapes RIA</p> <p>Deadline: 17 février 2027 (1^{ère} étape) + 16 septembre 2027 (2^{ème} étape)</p>	<p>4 projets 10M€/projet</p>	<p>Rigorous early-stage clinical trials (for pharmacological-based interventions: phase 1 and/or phase 2 clinical trials) into the safety and efficacy of the innovative interventions and their mode of administration</p> <p>Gain further insight into the potentially novel mechanism(s) of action of the innovative therapies and complementary approaches + analyses of imaging (MRI, ultrasound, nuclear imaging) + physiological, molecular, biochemical or omics signatures</p>	<p>Rare neurodegenerative diseases excluded</p>
---	---	-----------------------------------	---	---

Destination 5

Outils, technologies et solutions numériques pour la santé et les soins, y compris la médecine personnalisée

<p><u>HORIZON-HLTH-2027-03-TOOL-02:</u> Advancing bio-printing of living cells for regenerative medicine</p>	<p>2027 – 1 étape RIA</p> <p>Deadline : 16 septembre 2027</p>	<p>4 projets 7-10M€/projet</p>	<p>Develop or improve existing bioprinting equipment Scale-up the chosen bio-printing technology to a GMP-conform/compliant manufacturing process</p> <p>Enable the conduct of clinical studies and assess the clinical value of the developed bio-printing technology in first in-human studies</p>	<p>Any therapeutic area : any disease, dysfunction or defect</p> <p>Priority given to bio-printing approaches that either target vital internal organs followed by surgical grafting or employ in-situ approaches depositing the cell-laden bioink directly from the printhead on the defect target site in the body</p> <p>Sex differences at the cellular level should be taken into consideration</p>
<p><u>HORIZON-HLTH-2027-03-TOOL-04:</u> Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis</p>	<p>2027 – 1 étape RIA</p> <p>Deadline : 16 septembre 2027</p>	<p>4 projets 10-12M€/projet</p>	<p>Select clinical use cases to deliver multi-disciplinary high impact solutions requiring multi-organ, multi-scale approaches to modelling complex pathophysiology over time</p>	<p>Any areas of high disease burden; example areas include and are not limited to co-morbidities, chronic cardiovascular conditions, infection and (auto)immunity, inflammation and cancer, diabetes and related conditions, degenerative diseases (including their interaction with mental health conditions), exposome and its impact on human health and disease</p>

Destination 6

Industrie de la santé de l'UE soit innovante, durable et compétitive au niveau mondial grâce à une meilleure adoption des technologies et innovations de rupture

<u>HORIZON-HLTH-2027-01-IND-01:</u> Development of cell-free protein synthesis platforms for discovery and/or production of biologicals	2027 – 1 étape RIA Deadline : 17 février 2027	4 projets 6-8M€/projet	<p>Cell-free protein synthesis</p> <p>Use synthetic biology techniques for the design of de-novo biomolecules with specific desired properties (antimicrobial, immunogenic, angiogenic, etc.) and develop suitable cell-free systems for the high-throughput screening of the designed biomolecules</p> <p>Develop novel or optimize existing CFPS platforms for the production of the targeted biomolecule to a GMP-conform process, producing clinical-grade material that can be tested in clinical trials.</p>	
---	--	---------------------------	--	--

INNOVATIVE HEALTH INITIATIVE (IHI)



Partenariat public-privé prenant la suite d'Innovative Medicines Initiative

Partenariat institutionnel entre la CE et :

- Pharmaceutical companies (EFPIA)
- Radiological, electromedical, healthcare IT (COCIR)
- Medical technology companies (MedTechEurope)
- Biotechnology companies (EuropaBio)
- Vaccine companies (Vaccines Europe)



3 objectifs:

Transformer la recherche et l'innovation en matière de santé au bénéfice des **patients et de la société**

Délivrer des innovations de santé qui couvrent **l'ensemble du spectre des soins** (de la prévention au diagnostic et au traitement), en particulier dans les domaines où il existe un **besoin de santé publique non pourvu**

Rendre les **industries européennes de la santé compétitives** au niveau mondial


→ **Différents secteurs médicaux impliqués dans ce partenariat: soins de santé** → biopharma, biotechnologies, technologies médicales...

→ **3 AAP dans le cadre du call 13 à venir dont Topic 3 : Decode the Immuno-science of age-related mediated diseases**

- Better understanding of the potential causal links between chronic inflammatory diseases and biological aging
- **Repurposing or development of novel therapies for aging populations with chronic inflammatory diseases**
- Establishment of regulatory pathways for novel intervention strategies and biomarkers leading to faster clinical development of drugs that improve age-associated disease exacerbations,
- **Gastroenterological diseases:** IBD like Crohn's Disease, Ulcerative Colitis
- **Respiratory diseases:** like asthma, Chronic Obstructive Pulmonary Disease, Immune-mediated Interstitial Lung Disease
- **Rheumatoid diseases:** like Rheumatoid Arthritis, Giant Cell Arteritis, Polymyalgia Rheumatica, Sjögren's Disease, SLE
- Deadline (1ère étape): octobre + deadline (2ème étape): avril 2027





PROCEDURE APPELS A PROJETS IHI EN 2 ETAPES



EIC – CONSEIL EUROPÉEN DE L'INNOVATION

« Faire de l'Europe un leader de l'innovation »

1. Financer de l'innovation radicale à haut risque, créatrice de nouveaux marchés
2. « Dériskuer » pour attirer les investisseurs privés et soutenir les meilleurs innovateurs
3. Couvrir toute la chaîne de l'innovation (TRL 1 à 9) □ combler le fossé entre labo et marché
4. Appels Bottom-up et Top-down : détecter, développer des innovations de rupture très techno






EIC PATHFINDER

L'éclaireur...

Son rôle est de « Détecter et de développer des innovations technologiques radicales créatrices de marchés à moyen ou long terme. »

- **Recherche exploratoire** d'excellence inspirée par la **technologie « Deep Tech »**
- **La technologie ciblée (à 10 ans) doit être disruptive, à haut risque et fort potentiel**
- L'objet du projet est d'apporter la preuve de concept-principe/validation de la base scientifique en labo (TRL 3 ou 4)



« Pathfinder Open »

- appel à projet « **blanc** », ouvert à toutes les thématiques scientifiques et technologiques
- laisse l'opportunité à la communauté de recherche et d'innovation européenne de proposer des technologies ambitieuses sans les limiter à des domaines de recherche précis

« Pathfinder Challenges »

- appels **thématiques**, ciblant des domaines scientifiques et technologiques précis
- sollicite la communauté européenne de recherche et d'innovation afin d'apporter des solutions disruptives à des défis majeurs auxquels fait face l'Europe



EIC PATHFINDER CHALLENGE

Deadline : 28 octobre 2026

Total budget: 96 M€

3 disciplines :

- Digital
- Santé
- Environnement

Ce qui diffère /Open :


- Description dans le call de ce qui est attendu
- Evaluation
- Approche portefeuille

Qui peut déposer ?




Tout le monde ! universités, organismes de recherche, start-up, etc.

Projet Individuel OU collaboratif



- **Monobénéficiaire**
- Ou **2 bénéficiaires** issus de deux pays membres différents
- Ou au moins **3 entités légales** de [3 pays membres de l'UE ou associés](#) (consortium resserré)

Quel montant ? Budget ?



4 millions d'€ ou plus si justifié

Partie scientifique du dossier : 30 pages A4

EIC PATHFINDER CHALLENGE – TOPIC 2026

- 3 domaines
- budget global de 96M€ soit **8 projets retenus par challenge**

1/Advanced Materials for Miniaturised Energy Harvesting Systems

2/Biotechnology for Healthy Ageing

Identification of biomarkers or proof-of-concept validation of suitable pre-clinical models or bio-pharmaceutical interventions to prevent the emergence or reverts an age-related trait

1 des 3 objectifs à remplir :

- An innovative preventative or **therapeutic biotechnology-based or pharmaceutical intervention** that prevents, delays or reverts the onset of a **specific age-related disease**
- A **biomarker based tool** to enable the responsible deployment of ageing-related interventions
- A **New Approach Methodology (NAM)** that goes beyond the current state-of-the-art to enable the future development of interventions for healthy ageing

3/DeepRAP: Deep Reasoning, Abstraction & Planning towards trustworthy Cognitive AI Systems

BIOTECHNOLOGY FOR HEALTHY AGEING: CHALLENGE

Expected outcomes:

- **Proof-of-concepts** (TRL3 completed) of biotechnology-based or pharmaceutical interventions that prevents or delays the onset of, or reverts, an age-related disease in a vertebrate model system, based on the hallmarks of ageing, taking into consideration practical challenges of implementing such an intervention
- **Tools to facilitate development or adoption of the interventions** above, such as proof-of-concept validation of biomarker signatures or suitable pre-clinical models, and
- **Approaches to address the shared regulatory hurdles and societal challenges** linked to ageing-related interventions, thereby facilitating their adoption

BIOTECHNOLOGY FOR HEALTHY AGEING: CHALLENGE

- **Each objective is described in detail**, including concrete scientific criteria, required end points (PoC) and considerations related to further path of technology
- **Portfolio work:** Additionally, selected projects will be encouraged to collaborate to address shared challenges:
 - Scientific
 - Path to Market
 - SocietalA WP for portfolio work is recommended to be included in the proposal
 - this is **described in detail in the challenge guide**
- **Selection will take into consideration** individual proposal scores and portfolio considerations

LES DOCUMENTS DE REFERENCE



Challenge guide

Challenge Guide – Biotechnology for Healthy Ageing
Last Update 28-10-2025



PATHFINDER CHALLENGE

BIOTECHNOLOGY FOR HEALTHY AGEING

EIC Work Programme reference: HORIZON-EIC-2026-PATHFINDERCHALLENGES-01-02
Call deadline date: 28 October 2026 at 17h00 Brussels local time
EIC Programme Manager: Orsolya Symmons

The EIC will hold an Info Session on this Pathfinder Challenge topic on 30 March 2026 (TBC). Participation in the meeting, although encouraged, is optional and is not required for the submission of an application. A recording of this Info Session will be made available after the event. Further details of this (and possibly other) Info sessions will be disseminated through [Events - European Innovation Council - European Commission](#).

Table of Contents

1. About this document	2
2. Scope and objectives of the Challenge as defined in the Work programme	3
3. Portfolio considerations for the evaluation of applications to the Challenge	6
3.1 Categories.....	6
3.2 Portfolio considerations	7
4. Implementation of the Challenge portfolio	9
4.1 Proposal preparation and Grant negotiations	9
4.2 Portfolio Strategic Plan and portfolio activities	10
4.3 Governance through working groups.....	11
5. Tools though whi	12
Annex 1 : Template	13



Devenez Expert Évaluateur



AUPRÈS DE LA
COMMISSION EUROPÉENNE*

*Activité rémunérée



POURQUOI ?

- ✓ Enrichir ses connaissances en évaluant des projets scientifiques Horizon Europe
- ✓ Mieux comprendre les critères d'évaluation
- ✓ Améliorer l'écriture de son projet européen
- ✓ Construire ou étoffer son réseau

**MAISON
IRÈNE ET FRÉDÉRIC
JOLIOT-CURIE**

RESTER EN VEILLE SUR LES OPPORTUNITÉS POUR CONSTRUIRE VOTRE RESEAU ET ÊTRE VISIBLE



Groupe d'experts



Inserm | Cellule
Europe

CORDIS - Résultats de la recherche de l'UE

Accueil | Packs thématiques | Projets et résultats | Vidéos et podcasts | Actualités | Datalab | Recherche

Accueil > Recherche

Sauvegarder la recherche | Mes recherches sauvegardées | Télécharger mes résultats de recherche | RSS feed | Mon livret

micronano plastics

Filtres

Collection: Projets x Programme-cadre: Horizon Europe x

Inclure le contenu archivé

1 résultats pour 'micronano' AND 'plastics'

UPRISE Unravelling ultrafine particulate matter and micro nano plastic's mechanisms of impact on fetal health

Identifiant: 101156622

Du: 1 Janvier 2025 au: 31 Decembre 2029

The UPRISE project aims to unravel the complex mechanisms by which air pollution, in particular ultrafine particles (UFPs) and micro-nanoplastics (MNPs), disrupt normal fetal development leading to an increased risk of adverse birth outcomes (ABOs), including preterm birth...

Programme: [Health](#), [Health throughout the Life Course](#), [Environmental and Social Health Determinants](#)



**SUCCESSFUL
RESEARCHERS IN
INSERM EUROPEAN
PROJECTS**

2021 | 2022

[Lauréats des projets européens de
l'Inserm 2021 - 2022 \(calameo.com\)](https://calameo.com)



SUCCESSFUL CREATION & WRITING OF EU PROJECTS

11 JUNE, 2026

Content

01 About ABGi

02 Recap on EU funding opportunities

03 Creating a successful EU project

04 Grant writing in practice

05 Managing your funded project



A Fully Integrated Approach to Business Transformation

By bringing these capabilities together in a single, coordinated approach, ABGi offers clients one trusted partner to support transformation from strategy through to delivery.



Innovation

- Innovation Management & Processes
- Funding Strategy & Execution
- Delegation & Recruit
- Protection des inventions



Operations & Performance

- Procurement Policy and Strategy
- Operational Procurement Consulting
- Procurement Digitalisation
- Delegation and Recruitment
- Operational Excellence
- Energy



Technology

- Digital Transformation and Project Management
- Infrastructure
- Cloud & DevOps
- Data
- Security




ESG & Sustainability

- Non-Financial Performance and CSR Strategy
- CSRD and Sustainability Reporting
- Low Carbon Strategy
- Sustainable Innovation Strategy

ABOUT ABGI

ABGi, a unique player in the world of innovation consulting

ABGi (Visiativ subsidiary) is a pioneer and key player in the innovation financing and management market worldwide



ABGi supports its customers in accelerating their innovation :

by maximising

their R&D tax incentives in all the countries where they operate

by exploiting

all the grants and subsidies to which they are entitled

by improving

their innovation management

by reinforcing

their R&D teams and skills

ABGi, an international dimension, and a network of local agencies



... Coverage of all countries offering R&D incentives, through our offices and local contacts.

8 seats, 14 offices

Network of partners

>34 years
of experience

~76 M€
sales

>4 000
clients

>520
experts worldwide

98%
Client satisfaction

>2 Md€
of financing obtained for our customers each year

Applications for public grants & subsidies

Research | Development | Innovation | Investment



Analysis of the projects

- Positioning of the project in relation to the AAP



Construction of the project

- Definition of objectives, work packages, business plan



Assistance with finding partners

- At national, European and international level



File preparation

- Support drafting the application



Administrative and financial report

- Budget and budget and plan



Management of the funder's submission portal

- Collection and verification of documents
- Submitting your application



Coaching for oral presentations

- Preparation of project presentation material and speech



Agreement review, negotiation

- Negotiation of the agreement
- Preparation of documents for the contractualisation of the aid agreement



€30 M
in aid obtained every month

€5 B
in aid obtained for our clients

300
set-ups carried out every year

Experts Appraisers

bpifrance



Proposition pour PEPR


Equipe principale



10 consultants interlocuteurs techniques expérimentés



70% sont PhD



Dont 5 doctorats liés à la santé




+ 80 années d'expériences cumulées



+ 300 projets montés

Organigramme type par montage




KPI ABGi

	Nb projets déposés / acceptés	% de succès
Horizon Europe – Pilier 2	85 / 34	40%
Horizon Europe – Réseaux doctoraux MSCA	11 / 4	36%
Horizon Europe – EIC Pathfinder	4 / 1	25%
IHI	1 / 0	0
H2020	68 / 32	47%


Horizon Europe framework and other EU initiatives in the Health sector



2021 - 2027
Budget: 95,5 Md€



European Health Data Space



Various funding opportunities focusing on different TRL levels



A collection of logos for various funding programs: ERC (orange dots), F.E.D.E.R. (European Union flag), eurostars (blue 'e' with star), EUREKA (black square with white symbols), MSCA (purple shield with flag), EUROPEAN DEFENCE FUND (orange and blue), F.E.D.E.R. (European Union flag), Life (blue circle with stars and 'Life' text), and eit Health (green and blue circle).

Horizon Europe – Cluster calls for projects


Instrument		Grant Funding rate	Minimum Consortium	TRL	Type of activity	Proposal page limit
RIA	Research and Innovation Action	100% for all	3 partners / 3 countries	TRL1 -> TRL6	R&D, Demonstration, communication	45
IA	Innovation Action	70% or 60% « for profit » 100% « non profit »	3 partners / 3 countries	TRL5 -> TRL8	R&D, Demonstration, communication	45 or 70
CSA	Coordination and Support Action	100% for all	1 partner	N/A	No R&D: Impact assessment, networking , roadmap analysis...	30

What is a project?

A project is:

- A team → Mono-beneficiary (internal team), Collaborative project (consortium), sub-contracters, third parties, etc..
- Who will accomplish a set of tasks → Workplan with work packages, Gantt chart and PERT diagram, implementation actions
- In a defined timeframe →
- With a specific budget → Detailed budget xls
- To achieve objectives → Describing context, problems/challenges to address, specific goals
- That respond to a problem and →
- That will have an impact → Job creation, environmental impacts, economic-technological impacts, societal impacts, national/EU sovereignty, etc..

Defining a clear project:



Top-down funding strategy through the EU funding portal : Funding & Tenders

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/calls-for-proposals?status=31094501,31094502&order=DESC&pageNumber=1&pageSize=50&sortBy=startDate>

The screenshot shows the 'EU Funding & Tenders Portal' interface. The top navigation bar includes 'Home', 'Funding', 'Procurement', 'Projects & results', 'News & events', 'Work as an expert', and 'Guidance & documents'. A search bar is located on the right. Below the navigation, the breadcrumb trail reads 'Home > Funding > Calls for proposals'. The main heading is 'Calls for proposals', followed by a descriptive paragraph and a 'More details' link. A 'Filters' section on the left includes a 'Quick search' box with 'Digital' entered, and several filter buttons: '2021 - 2027', 'Horizon Europe (HORIZON)', 'Call', 'Submission status', and 'All filters'. The main content area shows '62 item(s) found' and a list of results. The first result is 'Development of smart concepts of integrated energy driven bio-refineries for co-production of advanced biofuels, bio-chemicals and biomaterials' (HORIZON-CL5-2024-D3-02-03), with an opening date of 17 September 2024 and a next deadline of 21 January 2025. The second result is 'Robotics and other automated solutions for construction, renovation and maintenance in a sustainable built environment (Built4People Partnership)' (HORIZON-CL5-2024-D4-02-02), also with an opening date of 17 September 2024 and a next deadline of 21 January 2025. The third result is 'BIM-based processes and digital twins for facilitating and optimising circular energy renovation (Built4People Partnership)' (HORIZON-CL5-2024-D4-02-03), with the same opening and deadline dates. Each result includes a 'Forthcoming' status indicator.

Parts of the proposal

Administrative part (Part A): Participant portal

Abstract / Keywords / duration

PIC / Contact person / partner description

Ethics questionnaire

Budget




Proposal description (Part B):

Section 1-3: Excellence / Impact / Implementation


45 / 70 pages




- I EXCELLENCE**
 - 1.1 OBJECTIVES AND AMBITIONS
 - 1.2 METHODOLOGY
- II IMPACT**
 - 2.1 PROJECT'S PATHWAYS TOWARDS IMPACT
 - 2.2 MEASURES TO MAXIMISE IMPACT - DISSEMINATION, EXPLOITATION AND COMMUNICATION
 - 2.3 SUMMARY (*canevas*)
- III QUALITY AND EFFICIENCY OF THE IMPLEMENTATION**
 - 3.1 WORK PLAN AND RESOURCES
 - 3.2 CAPACITY OF PARTICIPANTS AND CONSORTIUM AS A WHOLE



Key steps in project maturation and writing



Understanding the HE submission and evaluation timeline



- Selection criteria:**
- Excellence : x/5 (min 3)
 - Impact (x 1,5 pour IA): x/5 (min 3)
 - Implementation: x/5 (min 3)
 - Total x/15 (min 10)

Horizon Europe – typical project

—

Typical project

- Total of 5-10 partners (mixture of any type: SME, Large Groupe, RTO, University, Cluster, ...)
- 3-4 years project duration
- 4-10 M€ budget, 100% funding in most cases
- TRL 3-7 (most of the time)
- Supported by an Advisory Board (not obligatory)

Complementary team

- Interdisciplinary (technical, SSH, along the value chain)
- Involvement of end-users for validation
- Experts in Dissemination and Communication
- International team consisting of both junior, senior, male and female members

European sovereignty is key, business cases should be identified

Finding partners: <https://horizoneuropencportal.eu/sites/default/files/2022-05/guide-for-ps-tool.pdf>

EC Partner Search Tool

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search>

EURAXESS

<https://euraxess.ec.europa.eu/partnering>

NCP NETWORKS

EEN

<https://een.ec.europa.eu/partners>

F&T portal

Partner search

72

Organisations are looking for collaborating partners for this topic

[View / Edit](#)

LEARs, Account Administrators or self-registrants can publish partner requests for open and forthcoming topics after logging into this Portal.

CORDIS

<https://cordis.europa.eu/projects/en>

Use additional tools to ensure legislative alignment and high impact of your project

Google

Keywords of my topic, year, report/review/etc. X

Global No.1 Business Insights and facts across 170 countries

Size of the global market for electric vehicles in 2019 and 2027 (in billion U.S. dollars)

Year	Market Size (billion U.S. dollars)
2019	17.48
2027	224.14

eurostat

Your key to European statistics

European Commission > Eurostat > Home

EUROPEAN STATISTICAL Recovery Dashboard

WHAT'S NEW

- 17/01/2022 Household expenditure changes in the EU Member States
- 14/01/2022 Rents up by 18%, house prices by 39% since 2010
- 14/01/2022 Excess mortality increased again in November 2021
- 13/01/2022 Employment up, labour market slack down in Q3 2021

EURO INDICATORS

11/01/2022 EU current account surplus €72.1 bn

In the third quarter of 2021, the EU seasonally adjusted current account of the balance of payments recorded a surplus of €72.1 billion (2.0% of GDP), down from a surplus of €103.3 billion (2.6% of GDP) in the second quarter of 2021 and down from a surplus of €88.1 billion (2.6% of GDP) in the...

3six.com

EUROPE'S ENERGY ROADMAP 2050

Follow the 5 Generations

Europe has a goal of reducing its emissions by 90-95% by 2050. But what will Europe's energy landscape look like in 2050? And what routes will Europe take towards decarbonisation?

1 High Energy Efficiency: Political culture smart to rely high energy savings, intensive building retrofits and string regulations for new buildings and appliances.

2 Technologies Compete Openly: Technologies compete on a market basis, without any price intervention or support, although with a carbon price.

3 High Renewable Energy Shares: Society support for renewable energy leading to a very high share of renewables in gross final energy and electricity consumption.

4 Delayed CCS: Technology competes on a market basis but CCS Capture Capture Storage is delayed, leading to more nuclear.

5 Low Fossil: Technology competes on a market basis but assuming no new nuclear, requiring more CCS (carbon capture storage).

NextGenerationEU: Make it real

Find out more

What we do: EU renews its role in setting priorities, and its implementation through EU policy.

Who we are: Organisms, departments, roles and responsibilities, governing principles, and how to visit and get involved.

8 Commission priorities for 2019-24

The European Commission's political leadership

EUROPEAN COMMISSION

Brussels, 9.3.2021 COM(2021) 118 final

COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

2030 Digital Compass: the European way for the Digital Decade

EUROPEAN COMMISSION

Brussels, 19.11.2020 COM(2020) 741 final

COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

An EU Strategy to harness the potential of offshore renewable energy for a climate neutral future

European Commission

HORIZON EUROPE

The second STRATEGIC PLAN 2025-2027 sets direction to the future of R&I

Industry Association Websites
Websites on specific topics
...

Take home messages

- Each entity might be eligible for certain calls for projects, but not others, but all together, the **whole funding landscape is covered**.
- **Horizon Europe call for projects cover various TRL levels**
 - RIA (low-medium TRL),
 - IA (high TRL),
 - CSA (no TRL)
- **Any kind of entity can apply to these calls**
 - SMEs → special focus EIC Accelerator or Transition, often partner in HE/EIC Pathfinder projects
 - Universities/RTOs → mainly partners in HE/EIC Pathfinder/EIC Transition projects
 - Large Groups → often coordinator of HE projects, involved as end-user in EIC Transition projects
 - Clusters of Excellence → special focus HE, often involved in CSA actions and/or Dissemination/Communication role in RIA/IA
- **Each call has its own particularities with regards to consortium composition, expected budgets, TRL levels, format of proposal, submission timeline, selection criteria, etc**
 - Always compare your project ideas to the expectations of the calls
 - Make sure to download the latest version of the official template for proposals

Mirelle TER VEER

Program Leader

mirelle.ter-veer@abgi-france.com



BRAZIL • CANADA • FRANCE
GERMANY • IRELAND • POLAND
UNITED KINGDOM • UNITED STATES

Any questions?

Angers • Aix-en-Provence
Bordeaux • Grenoble • Lyon
Paris • Strasbourg • Toulouse

ABGI France
52 quai Rambaud
69002 LYON
contact@abgi-france.com
Tél. +33 4 78 92 40 00



www.abgi-france.com